Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Microbiology

• Publication date

  2008-06-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JCM.00566-08PMID 18579718PMCID PMC2519503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

  2008influential reference
• A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

  2008cited by this paper
• PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING, NINTH INFORMATIONAL SUPPLEMENT

  2008cited by this paper
• In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

  2008influential reference
• Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement

  2008cited by this paper
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

  2007cited by this paper
• In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model

  2007cited by this paper
• The Echinocandins

  2007influential reference
• Resistance to echinocandin-class antifungal drugs.

  2007influential reference
• Effects of Serum on In Vitro Susceptibility Testing of Echinocandins

  2007cited by this paper
• ECHINOCANDIN ANTIFUNGAL DRUG RESISTANCE

  2007cited by this paper
• Serum Differentially Alters the Antifungal Properties of Echinocandin Drugs

  2007cited by this paper
• Anidulafungin versus fluconazole for invasive candidiasis.

  2007cited by this paper
• In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance

  2007cited by this paper
• Acquired resistance to echinocandins in Candida albicans: case report and review.

  2007cited by this paper
• Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase

  2007influential reference
• Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

  2007cited by this paper
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

  2007influential reference
• Micafungin: a new echinocandin.

  2006cited by this paper
• Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis

  2006cited by this paper
• Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

  2006cited by this paper
• Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia

  2006cited by this paper
• Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility

  2006cited by this paper
• Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

  2006cited by this paper
• Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

  2006cited by this paper
• Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods

  2006cited by this paper
• Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp

  2006cited by this paper
• Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

  2006cited by this paper
• Pharmacology of Systemic Antifungal Agents

  2006influential reference
• Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy

  2006cited by this paper
• Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1

  2006influential reference
• Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin

  2006cited by this paper
• Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

  2005influential reference
• International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

  2005cited by this paper
• A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis

  2005cited by this paper
• In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

  2005cited by this paper
• Anidulafungin: a new echinocandin with a novel profile.

  2005cited by this paper
• Echinocandins: role in antifungal therapy, 2005

  2005cited by this paper
• Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis

  2005cited by this paper
• Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome

  2005influential reference
• Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

  2005cited by this paper
• Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

  2004cited by this paper
• Anidulafungin: an echinocandin antifungal

  2004cited by this paper
• Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

  2004cited by this paper
• Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

  2004cited by this paper
• Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates

  2004cited by this paper
• Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

  2004cited by this paper
• In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

  2003cited by this paper
• Caspofungin.

  2003cited by this paper
• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

  2003cited by this paper
• In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis

  2003cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002cited by this paper
• In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance

  2002cited by this paper
• In Vitro Activity of Micafungin (FK-463) against Candida spp.: Microdilution, Time-Kill, and Postantifungal-Effect Studies

  2002cited by this paper
• A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

  2002cited by this paper
• Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

  2002cited by this paper
• Has antifungal susceptibility testing come of age?

  2002cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

  2001cited by this paper
• Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans

  2000cited by this paper
• In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.

  1999cited by this paper
• Development of in vitro susceptibility testing criteria and quality control parameters

  1989cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Letter to the Editor regarding 'Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study'

  2026cites this paper
• Antimicrobial resistance and real-time PCR detection of blaKPC in Klebsiella pneumoniae isolated from wound infections in a tertiary care hospital

  2026cites this paper
• Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development

  2026cites this paper
• Screening a 681-membered yeast collection for the secretion of proteins with antifungal activity.

  2025cites this paper
• Variations in virulence factors, antifungal susceptibility and extracellular polymeric substance compositions of cryptic and uncommon Candida species from oral candidiasis

  2025cites this paper
• Predictors of caspofungin exposure-response relationship: a retrospective cohort study on therapeutic drug monitoring parameters

  2025cites this paper
• In vitro assessment of cefepime adsorption in filters used during renal replacement therapy

  2025cites this paper
• Evolutionary trends in antifungal resistance: a meta-analysis

  2024cites this paper
• Optimal dosing regimen of caspofungin in adolescents with allogeneic haematopoietic stem cell transplantation.

  2024cites this paper
• Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis

  2023cites this paper
• ANTIFUNGAL DRUG RESISTANCE PATTERN AMONG BIOFILM PRODUCING STRAINS OF CANDIDA SPECIES ISOLATED FROM BLOODSTREAM INFECTIONS

  2022cites this paper
• Drug-dependent growth curve reshaping reveals mechanisms of antifungal resistance in Saccharomyces cerevisiae

  2022cites this paper
• Update on the Pathogenesis, Virulence, and Treatment of Candida auris

  2022cites this paper
• Synergistic Antifungal Activity of Phellodendri Cortex and Magnoliae Cortex against Candida albicans

  2022cites this paper
• A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis

  2021cites this paper
• Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study

  2021cites this paper
• Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study

  2021cites this paper
• Echinocandins

  2021cites this paper
• Fungal infections—Background to specific fungal species

  2021cites this paper
• Hematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species

  2021cites this paper
• Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations

  2020cites this paper
• Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections

  2020cites this paper
• Antifungal Susceptibility of Non-albicans Candida Species in A Tertiary Care Hospital, Bulgaria

  2020cites this paper
• An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

  2020cites this paper
• Elevated Vacuolar Uptake of Fluorescently Labeled Antifungal Drug Caspofungin Predicts Echinocandin Resistance in Pathogenic Yeast

  2020cites this paper
• Synergistic Effects and Mechanisms of Combined Treatment With Harmine Hydrochloride and Azoles for Resistant Candida albicans

  2019cites this paper
• Species Distribution and Antifungal Susceptibility Profile of Yeasts Recovered from Different Clinical Samples at Arsho laboratory, Addis Ababa, Ethiopia.

  2019cites this paper
• The Magnitude of Candida albicans Stress-Induced Genome Instability Results from an Interaction Between Ploidy and Antifungal Drugs

  2019cites this paper
• Acquired multidrug‐resistant Candida glabrata in Australia: a case report

  2019cites this paper
• ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients

  2019cites this paper
• Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment.

  2019cites this paper
• Ploidy determines the consequences of antifungal-induced mutagenesis in Candida albicans, a human fungal pathogen

  2019cites this paper
• Comparison of fks gene mutations and minimum inhibitory concentrations for the detection of Candida glabrata resistance to micafungin: A systematic review and meta‐analysis

  2019cites this paper
• Micafungin as antifungal prophylaxis in non-transplanted haemotological patients

  2019cites this paper
• Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole

  2019cites this paper
• Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance

  2018cites this paper
• In vitro Antifungal Susceptibility Profiles of Echinocandins and Triazoles for Clinical Opportunistic Candida isolates by E-test method

  2018cites this paper
• Overview of antifungal dosing in invasive candidiasis.

  2018cites this paper
• Ассоциированная с мутациями генов FKS резистентность Candida glabrata к эхинокандинам: насколько актуальна проблема?

  2018cites this paper
• Filter Adsorption of Anidulafungin to a Polysulfone‐Based Hemofilter During CVVHD In Vitro

  2018cites this paper
• Antifungal Susceptibility Profiles of Candida Species Isolated from Ahvaz Jundishapur Educational Hospitals

  2018cites this paper
• Echinocandins in Ocular Therapeutics

  2017cites this paper
• Optimization of anti-infective dosing regimens during online haemodiafiltration

  2017cites this paper
• Caspofungin infusion solutions (50 mg/100 mL): chemical stability and antifungal activity against Candida spp.

  2017cites this paper
• Antimicrobial Drug Resistance

  2017influential citation
• Candida parapsilosis associated with cervical necrotizing fasciitis and descending mediastinitis

  2017cites this paper
• Coprocultures quantitatives à levures au CHU de Caen : caractérisation épidémiologique, phénotypique et moléculaire

  2017cites this paper
• Antifungal PK/PD in the critically Ill

  2017cites this paper
• Towards cost-effective utilisation of high-cost antifungal agents in Australian hospitals

  2017cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins

  2016cites this paper
• Antifungal pharmacodynamics: Latin America's perspective

  2016cites this paper
• Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes

  2016influential citation
• Therapeutic drug monitoring of anti-infective agents in critically ill patients

  2016cites this paper
• The activity of micafungin against clinical isolates of non-albicans Candida spp.

  2015cites this paper
• Antifungal drug resistance among Candida species: mechanisms and clinical impact

  2015cites this paper
• SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY

  2015cites this paper
• Mechanisms of Antifungal Drug Resistance.

  2015cites this paper
• The role of the FKS1 gene in nosocomial Candida albicans isolates' virulence and antifungal resistance

  2015cites this paper
• SOLIDAGO CHILENSIS ESSENTIAL OIL AS A POTENTIAL NEW DRUG AGAINST RESISTANT CANDIDA ISOLATES, WITHOUT HUMAN BLOOD CELL DAMAGE AND GENOTOXICITY

  2015cites this paper
• Antifungal pharmacokinetics and pharmacodynamics.

  2015cites this paper
• [In vitro susceptibility of isolates of Paracoccidioides spp complex to systemic antifungals using the microdilution method].

  2015cites this paper
• Mechanisms of Resistance to Antifungal Agents

  2015cites this paper
• Mechanisms of Action of Antifungal Agents

  2015cites this paper
• Echinocandin Resistance in Candida.

  2015cites this paper
• New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study

  2015cites this paper
• Identification and Characterization of a Rare Fungus, Quambalaria cyanescens, Isolated from the Peritoneal Fluid of a Patient after Nocturnal Intermittent Peritoneal Dialysis

  2015cites this paper
• Controversies in Candida management.

  2015cites this paper
• Fungal Biomarkers, Antifungal Susceptibility Testing, and Therapeutic Drug Monitoring—Practical Applications for the Clinician in a Tertiary Care Center

  2015cites this paper
• and Interpretive Criteria of Candida by Using CLSI Methods and Caspofungin among 4 , 290 Clinical Isolates To Predict Susceptibility and Resistance to Use of Anidulafungin as a Surrogate Marker

  2014cites this paper
• Caspofungin exposure‐response relationships in adult patients with mucosal or invasive candidiasis

  2014cites this paper
• Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection

  2014cites this paper
• Synthesis and evaluation of novel azoles as potent antifungal agents.

  2014cites this paper
• Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria

  2014cites this paper
• Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non‐albicans Candida species

  2014cites this paper
• The evaluation of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates by etest and disk diffusion methods.

  2014cites this paper
• Antifungal drug discovery: the process and outcomes.

  2014cites this paper
• Antifungal resistance does not necessarily affect Candida glabrata fitness

  2014cites this paper
• Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

  2014cites this paper
• Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

  2014cites this paper
• Treatment of Candida Glabrata With Micafungin: A Case Report and Brief Review of the Literature

  2013cites this paper
• Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

  2013cites this paper
• Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

  2013cites this paper
• [Susceptibility of Candida albicans blood isolates to 3 antifungal drugs: retrospective study in Rio Grande do Sul, Brazil, 1999-2009].

  2013cites this paper
• Candida Fermentati: A Rare Yeast Involved in Fungal Keratitis

  2013cites this paper
• Candida and candidaemia. Susceptibility and epidemiology.

  2013cites this paper
• Universidade Federal do Rio Grande do Sul Faculdade de Medicina Programa de Pós Graduação em Ciências Pneumológicas

  2013cites this paper
• Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria

  2013cites this paper
• Synergistic effect of doxycycline and fluconazole against Candida albicans biofilms and the impact of calcium channel blockers.

  2013cites this paper
• Intracellular concentrations of anidulafungin in different compartments of the peripheral blood.

  2013cites this paper
• Les échinocandines : mise au point

  2013cites this paper
• Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure

  2013cites this paper
• Impact of the new clinical Breaking points proposed by the clinical and Laboratory standards Institute (cLsI) in the Antifungal Susceptibility Profile of Clinical Strains Isolated from Invasive Bloodstream Candida Spp . Infections in spain

  2012cites this paper
• Utility of Antifungal Susceptibility Testing and Clinical Correlations

  2012cites this paper
• Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison

  2012cites this paper
• Interactions of Yeasts, Moulds, and Antifungal Agents

  2012cites this paper
• Echinocandin Antifungal Drugs in Fungal Infections

  2012cites this paper
• Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer.

  2012cites this paper
• Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

  2012cites this paper
• In vitro Susceptibilities of Iranian Clinical non-albicans Candida species to Caspofungin and Ketoconazole

  2012cites this paper